Chembio Financial Statements From 2010 to 2022

CEMI -  USA Stock  

USD 0.60  0.07  13.21%

Chembio Diagnostics financial statements provide useful quarterly and yearly information to potential Chembio Diagnostics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Chembio Diagnostics financial statements helps investors assess Chembio Diagnostics' valuation, profitability, and current liquidity needs.
We have found eighty-six available fundamental signals for Chembio Diagnostics, which can be analyzed and compared to other ratios and to its rivals. Please verify all of Chembio Diagnostics prevailing fundamental drivers against the trend between 2010 and 2022 to make sure the company can sustain itself down the road.
Chembio Diagnostics Invested Capital Average is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital Average was reported at 52.23 Million. The current Market Capitalization is estimated to increase to about 53.6 M, while Average Assets are projected to decrease to roughly 53.1 M.
  
Refresh
Check Chembio Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chembio main balance sheet or income statement drivers, such as Cost of Revenue of 28.6 M, Gross Profit of 13.3 M or Interest Expense of 3.1 M, as well as many exotic indicators such as Asset Turnover of 0.84, Book Value per Share of 1.46 or Current Ratio of 4.17. Chembio financial statements analysis is a perfect complement when working with Chembio Diagnostics Valuation or Volatility modules. It can also supplement various Chembio Diagnostics Technical models. Continue to the analysis of Chembio Diagnostics Correlation against competitors.

Chembio Diagnostics Revenues

41.89 Million

Share

Chembio Diagnostics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets58.3 M73.3 M34.5 M
Increasing
Slightly volatile
Cash and Equivalents31 M28.8 M12 M
Increasing
Slightly volatile
Deferred RevenueM1.8 M653.3 K
Increasing
Slightly volatile
Deposit Liabilities20.8 K20.9 K22.9 K
Decreasing
Slightly volatile
Property Plant and Equipment Net15.8 M14.6 M5.8 M
Increasing
Slightly volatile
Inventory10.3 M12.9 MM
Increasing
Slightly volatile
Tax Assets5.9 M6.3 M5.1 M
Increasing
Slightly volatile
Trade and Non Trade Receivables12.3 M11.4 M5.4 M
Increasing
Slightly volatile
Trade and Non Trade Payables14.2 M13.1 M5.8 M
Increasing
Slightly volatile
Goodwill and Intangible Assets3.7 MM3.4 M
Increasing
Slightly volatile
Total Liabilities42.1 M39 M14.4 M
Increasing
Slightly volatile
Shareholders Equity30.3 M34.3 M21.3 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(608 K)(592.4 K)20.2 K
Decreasing
Slightly volatile
Current Assets59.6 M55.2 M24.8 M
Increasing
Slightly volatile
Assets Non Current15.9 M18 M11.1 M
Increasing
Slightly volatile
Current Liabilities16.5 M15.3 M6.6 M
Increasing
Slightly volatile
Liabilities Non Current18.7 M23.7 M7.4 M
Increasing
Slightly volatile
Total Debt27.9 M25.9 M8.2 M
Increasing
Slightly volatile
Debt Current2.3 M2.2 M569.6 K
Increasing
Slightly volatile
Debt Non Current25.6 M23.7 M7.7 M
Increasing
Slightly volatile
Shareholders Equity USD30.3 M34.3 M21.3 M
Increasing
Slightly volatile
Cash and Equivalents USD31 M28.8 M12 M
Increasing
Slightly volatile
Total Debt USD27.9 M25.9 M8.2 M
Increasing
Slightly volatile

Chembio Diagnostics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues41.9 M47.8 M29.1 M
Increasing
Slightly volatile
Cost of Revenue28.6 M34.5 M18.2 M
Increasing
Slightly volatile
Selling General and Administrative Expense26.8 M24.8 M11.4 M
Increasing
Slightly volatile
Research and Development Expense10.9 M12.5 M7.6 M
Increasing
Slightly volatile
Operating Expenses47.9 M44.4 M20.5 M
Increasing
Slightly volatile
Interest Expense3.1 M2.9 M741.8 K
Increasing
Slightly volatile
Income Tax Expense(66.9 K)(62 K)(483.4 K)
Increasing
Slightly volatile
Consolidated Income(34.8 M)(33.9 M)(9.6 M)
Decreasing
Slightly volatile
Net Income(34.8 M)(33.9 M)(9.6 M)
Decreasing
Slightly volatile
Net Income Common Stock(34.8 M)(33.9 M)(9.6 M)
Decreasing
Slightly volatile
Weighted Average Shares20.2 M24.3 M13.1 M
Increasing
Slightly volatile
Weighted Average Shares Diluted20.3 M24.3 M13.3 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(31.9 M)(31.1 M)(9.4 M)
Decreasing
Slightly volatile
Revenues USD41.9 M47.8 M29.1 M
Increasing
Slightly volatile
Net Income Common Stock USD(34.8 M)(33.9 M)(9.6 M)
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(31.9 M)(31.1 M)(9.4 M)
Decreasing
Slightly volatile
Gross Profit13.3 M13.3 M10.9 M
Increasing
Slightly volatile
Operating Income(31.9 M)(31.1 M)(9.4 M)
Decreasing
Slightly volatile

Chembio Diagnostics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals44.4 K41.2 K(770.3 K)
Increasing
Very volatile
Net Cash Flow from Financing41.7 M38.7 M14.1 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities (63.5 K)(61.9 K)1.3 M
Increasing
Stable
Issuance Purchase of Equity Shares42 M38.9 M13 M
Increasing
Slightly volatile
Net Cash Flow from Operations(31.7 M)(30.9 M)(8.3 M)
Decreasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (246.8 K)(240.4 K)(18.9 K)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents6.2 M5.7 M2.6 M
Increasing
Slightly volatile
Share Based Compensation2.6 M2.4 M851.3 K
Increasing
Slightly volatile
Depreciation Amortization and Accretion3.2 M2.9 M1.4 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(1.44)(1.4)(0.4551)
Decreasing
Slightly volatile
Earnings per Diluted Share(1.44)(1.4)(0.4651)
Decreasing
Slightly volatile
Earnings per Basic Share USD(1.44)(1.4)(0.4551)
Decreasing
Slightly volatile
Return on Average Equity(1.16)(1.125)(0.2862)
Decreasing
Slightly volatile
Return on Average Assets(0.53)(0.513)(0.1433)
Decreasing
Slightly volatile
Return on Invested Capital(0.61)(0.594)(0.3099)
Decreasing
Slightly volatile
Gross Margin0.310.2790.3933
Decreasing
Slightly volatile
Profit Margin(0.73)(0.709)(0.254)
Decreasing
Slightly volatile
EBITDA Margin(0.6)(0.588)(0.2124)
Decreasing
Slightly volatile
Return on Sales(0.67)(0.649)(0.2568)
Decreasing
Slightly volatile
Asset Turnover0.840.7241.14
Decreasing
Slightly volatile
Enterprise Value over EBITDA(0.93)(0.859)(4.4587)
Decreasing
Slightly volatile
Enterprise Value over EBIT(1.08)(1.0)0.6093
Decreasing
Slightly volatile
Price to Earnings Ratio(0.83)(0.814)0.5936
Decreasing
Slightly volatile
Sales per Share2.041.9682.3542
Decreasing
Slightly volatile
Price to Sales Ratio0.590.5791.962
Increasing
Very volatile
Price to Book Value1.031.02.8899
Increasing
Very volatile
Debt to Equity Ratio1.231.1380.5463
Increasing
Slightly volatile
Current Ratio4.173.6143.8762
Increasing
Slightly volatile
Free Cash Flow per Share(1.38)(1.346)(0.5079)
Decreasing
Slightly volatile
Book Value per Share1.461.411.676
Decreasing
Slightly volatile
Tangible Assets Book Value per Share2.852.892.3038
Increasing
Slightly volatile

Chembio Diagnostics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(34.9 M)(34 M)(10.1 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(28.9 M)(28.1 M)(8 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(28.9 M)(28.1 M)(8 M)
Decreasing
Slightly volatile
Market Capitalization53.6 M34.3 M58.1 M
Increasing
Slightly volatile
Enterprise Value24.8 M24.2 M51.9 M
Increasing
Slightly volatile
Invested Capital56.1 M52 M22.6 M
Increasing
Slightly volatile
Average Equity27.5 M30.1 M19.7 M
Increasing
Slightly volatile
Average Assets53.1 M66.1 M31.7 M
Increasing
Slightly volatile
Invested Capital Average56.4 M52.2 M21.6 M
Increasing
Slightly volatile
Tangible Asset Value75.8 M70.2 M33.1 M
Increasing
Slightly volatile
Free Cash Flow(33.6 M)(32.7 M)(9.8 M)
Decreasing
Slightly volatile
Working Capital43.1 M39.9 M18.2 M
Increasing
Slightly volatile

Chembio Fundamental Market Drivers

Short Percent Of Float10.69%
Forward Price Earnings-0.56
Shares Short Prior Month2.67M
Average Daily Volume Last 10 Day201.14k
Average Daily Volume In Three Month280.68k
Date Short Interest15th of December 2021
Fifty Day Average0.7106
Two Hundred Day Average1.6386

Chembio Upcoming Events

Upcoming Quarterly Report10th of March 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Chembio Diagnostics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Chembio Diagnostics income statement, its balance sheet, and the statement of cash flows. Chembio Diagnostics investors use historical funamental indicators, such as Chembio Diagnostics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Chembio Diagnostics investors may use each financial statement separately, they are all related. The changes in Chembio Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Chembio Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Chembio Diagnostics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Chembio Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue1.8 MM
Cost of Revenue34.5 M28.6 M
Revenues47.8 M41.9 M
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or diagnose diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York. Chembio Diagnostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 355 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chembio Diagnostics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Pair Trading with Chembio Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chembio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chembio Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Chembio Diagnostics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Chembio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chembio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chembio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chembio Diagnostics to buy it.
The correlation of Chembio Diagnostics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chembio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chembio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chembio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Chembio Diagnostics Correlation against competitors. Note that the Chembio Diagnostics information on this page should be used as a complementary analysis to other Chembio Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Chembio Stock analysis

When running Chembio Diagnostics price analysis, check to measure Chembio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chembio Diagnostics is operating at the current time. Most of Chembio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Chembio Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chembio Diagnostics' price. Additionally, you may evaluate how the addition of Chembio Diagnostics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.